Zetia Related Published Studies
Well-designed clinical trials related to Zetia (Ezetimibe)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce
low-density lipoprotein cholesterol in patients with heterozygous familial
hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a
phase 2 randomised controlled trial. [2012]
The effect of ezetimibe and simvastatin on hemostasis in patients with isolated
hypercholesterolemia. [2012]
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). [2011.08.15]
Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans. [2011.08.02]
The ezetimibe controversy: implications for clinical practice. [2011.08]
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. [2011.06.25]
Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. [2011.06.01]
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. [2011.06]
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. [2011.05]
Benefit and tolerability of the coadministration of ezetimibe and atorvastatin in acute coronary syndrome patients. [2011.04]
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. [2011.04]
Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. [2011.04]
Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. [2011.04]
The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. [2011.04]
Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. [2011.04]
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. [2011.03]
The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A. [2011.02]
Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. [2011]
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus
rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. [2011]
Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis
of 22,231 hyperlipidemic patients. [2011]
Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a
randomized, controlled feeding study in humans. [2011]
Achievement of recommended lipid and lipoprotein levels with combined
ezetimibe/statin therapy versus statin alone in patients with and without
diabetes. [2011]
Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe. [2010.12]
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. [2010.11.10]
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. [2010.11.04]
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). [2010.11.01]
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. [2010.11]
Application of one-step liquid chromatography-electrospray tandem MS/MS and collision-induced dissociation to quantification of ezetimibe and identification of its glucuronated metabolite in human serum: A pharmacokinetic study. [2010.10.15]
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. [2010.10]
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. [2010.09]
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. [2010.07.27]
Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. [2010.07.15]
Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. [2010.07]
Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. [2010.07]
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. [2010.07]
Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. [2010.06.15]
Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. [2010.06]
Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. [2010.06]
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. [2010.06]
Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). [2010.05.21]
Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy). [2010.05.15]
The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. [2010.05]
Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. [2010.05]
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. [2010.05]
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. [2010.05]
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. [2010.04]
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). [2010.03.01]
Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. [2010.03]
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. [2010.02.15]
Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. [2010.02]
Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. [2010.01]
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. [2010.01]
Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease
patients. [2010]
Attainment of Canadian and European guidelines' lipid targets with atorvastatin
plus ezetimibe vs. doubling the dose of atorvastatin. [2010]
Ezetimibe + simvastatin versus doubling the dose of simvastatin in high
cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). [2010]
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and
rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of
achievement of Joint British Societies (JBS-2) cholesterol targets. [2010]
Colesevelam added to combination therapy with a statin and ezetimibe in patients
with familial hypercholesterolemia: a 12-week, multicenter, randomized,
double-blind, controlled trial. [2010]
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of
atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the
ELDerly [ZETELD] study). [2010]
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in
patients at high risk for coronary heart disease with diabetes mellitus,
metabolic syndrome or neither. [2010]
Indices of cholesterol metabolism and relative responsiveness to ezetimibe and
simvastatin. [2010]
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. [2009.12.17]
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. [2009.12]
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. [2009.12]
Extended-release niacin or ezetimibe and carotid intima-media thickness. [2009.11.26]
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. [2009.07]
Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. [2009.07]
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). [2009.06.15]
Effect on serum lipid levels of switching dose of ezetimibe from 10 to 5 mg. [2009.06.01]
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. [2009.06]
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. [2009.04]
The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. [2009.03.15]
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. [2009.01.06]
The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. [2009.01]
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. [2009]
Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. [2009]
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. [2008.12.16]
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. [2008.12.01]
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. [2008.12.01]
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. [2008.12]
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. [2008.12]
Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. [2008.11]
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. [2008.10.15]
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. [2008.09.25]
Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. [2008.07]
Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. [2008.05]
SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. [2008.05]
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. [2008.04.22]
Simvastatin with or without ezetimibe in familial hypercholesterolemia. [2008.04.03]
Left atrial volume in patients with asymptomatic aortic valve stenosis (the Simvastatin and Ezetimibe in Aortic Stenosis study). [2008.04.01]
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. [2008.03]
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. [2008.01]
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. [2007.12]
Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. [2007.08.28]
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). [2007.06]
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. [2007.04.01]
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. [2007.04]
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? [2007.03.13]
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). [2007.03.01]
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. [2007.02]
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. [2006.12]
The lipid-lowering effect of ezetimibe in pure vegetarians. [2006.12]
|
